Download Powerpoint - Blood Advances

Survey
yes no Was this document useful for you?
   Thank you for your participation!

* Your assessment is very important for improving the workof artificial intelligence, which forms the content of this project

page
1
page
2
page
3
page
4
page
5
page
6
Document related concepts
no text concepts found
Transcript 
Network meta-analysis of randomized trials in multiple
myeloma: efficacy and safety in relapsed/refractory
patients
by Cirino Botta, Domenico Ciliberto, Marco Rossi, Nicoletta Staropoli, Maria Cucè,
Teresa Galeano, Pierosandro Tagliaferri, and Pierfrancesco Tassone
BloodAdv
Volume 1(7):455-466
February 28, 2017
© 2017 by The American Society of Hematology
Cirino Botta et al. Blood Adv 2017;1:455-466
© 2017 by The American Society of Hematology
PRISMA flowchart for study selection and review.
Cirino Botta et al. Blood Adv 2017;1:455-466
© 2017 by The American Society of Hematology
Forest plots of comparisons between experimental treatments and standard treatments in terms
of PFS and OS. Bortezomib (BORT) with or without dexamethasone represents the standard
treatment (ST) in (A) PFS and (C) OS; IMiDs represent the standard treatment in (B) PFS and (D)
OS. Subgroups have been created according to drug classes.
Cirino Botta et al. Blood Adv 2017;1:455-466
© 2017 by The American Society of Hematology
Network of the comparisons and comparative efficacy and tolerance results.
Cirino Botta et al. Blood Adv 2017;1:455-466
© 2017 by The American Society of Hematology
Ranking of treatments based on NMA results.
Cirino Botta et al. Blood Adv 2017;1:455-466
© 2017 by The American Society of Hematology
Related documents